Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry
Background Tumour necrosis factor (TNF)-inhibiting therapy increases the risk of serious infections in rheumatoid arthritis (RA). However, it is not clear whether this risk differs between TNF inhibitors. Objective To analyse whether the risk of serious infections in patients with RA treated with an anti-TNF inhibitor is different for adalimumab, infliximab and etanercept. Methods Data from the Dutch RA monitoring registry were used. Incidence rates were calculated from the observed number of first serious infections and follow-up time up to 5 years. A Cox proportional hazards model... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | TEXT |
Erscheinungsdatum: | 2012 |
Verlag/Hrsg.: |
BMJ Publishing Group Ltd
|
Schlagwörter: | Clinical and epidemiological research |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-27410736 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | http://ard.bmj.com/cgi/content/short/annrheumdis-2012-201338v1 |